Return to study ST001013 main page
MB Sample ID: SA063611
Local Sample ID: | Sample # 12 |
Subject ID: | SU001052 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU001052 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
Sample # 12 | SA063611 | FL010891 | Weight Stable | Grouping |
Sample # 12 | SA063611 | FL010891 | Male | Gender |
Collection:
Collection ID: | CO001046 |
Collection Summary: | Tissue and blood donated from Cancer Cachexia Program at Ohio State University |
Sample Type: | Blood (serum) |
Treatment:
Treatment ID: | TR001066 |
Treatment Summary: | Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ¼ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation. |
Sample Preparation:
Sampleprep ID: | SP001059 |
Sampleprep Summary: | TCA concentrations using serum |
Combined analysis:
Analysis ID | AN001655 |
---|---|
Analysis type | MS |
Chromatography type | GC |
Chromatography system | Agilent 7890B |
Column | Agilent HP5-MS (30m × 0.25mm, 0.25 um) |
MS Type | EI |
MS instrument type | Single quadrupole |
MS instrument name | Agilent 5977A |
Ion Mode | POSITIVE |
Units | uM |
Chromatography:
Chromatography ID: | CH001166 |
Instrument Name: | Agilent 7890B |
Column Name: | Agilent HP5-MS (30m × 0.25mm, 0.25 um) |
Chromatography Type: | GC |
MS:
MS ID: | MS001530 |
Analysis ID: | AN001655 |
Instrument Name: | Agilent 5977A |
Instrument Type: | Single quadrupole |
MS Type: | EI |
Ion Mode: | POSITIVE |